Crescendo Bioscience is developing a broad range of quantitative, objective diagnostic tools to provide Rheumatologists with deeper clinical insights to more effectively manage patients with autoimmune and inflammatory diseases.

The Company is initially focused on rheumatoid arthritis, a debilitating, highly variable, chronic disease affecting over 1.5 million patients in the US and more than 3 million in Europe. Current diagnostic tools for assessing the status of rheumatoid arthritis sufferers are largely subjective, imprecise and cumbersome to administer in daily practice. Although there is no known cure, there are multiple therapeutics with widely differing effectiveness (and adverse reactions) in individual patients. Choosing among these treatment options is a tremendous challenge.

Working with collaborators in leading academic medical institutions, Crescendo Bioscience is building a comprehensive understanding of the biology underlying rheumatoid arthritis, including the characterization of protein and gene expression biomarkers, to provide molecular staging of the disease and guidance for the treatment of individual patients.

Crescendo's mission is to establish a long-term relationship with physicians by providing comprehensive diagnostic, prognostic, staging, therapy selection and monitoring capabilities to better improve outcomes over the lifetime of each patient. This includes advanced reporting and patient trending information. These tests and reporting capabilities will be performed at our own specialized, CLIA-certified laboratory.

Crescendo Bioscience is a privately held company, led by an experienced management and scientific team that has successfully developed and commercialized a wide range of relevant life science innovations. This Team possesses deep expertise in autoimmune diseases and novel technology applications. The Company was initially launched under the name Riley Genomics (RiGEN) to develop proprietary diagnostic technology originating from the Oklahoma Medical Research Foundation (OMRF), and is funded by two of the leading healthcare venture capital investors: Kleiner Perkins Caufield & Byers and Mohr Davidow Ventures.